307 related articles for article (PubMed ID: 31023702)
1. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
Mill CP; Fiskus W; DiNardo CD; Qian Y; Raina K; Rajapakshe K; Perera D; Coarfa C; Kadia TM; Khoury JD; Saenz DT; Saenz DN; Illendula A; Takahashi K; Kornblau SM; Green MR; Futreal AP; Bushweller JH; Crews CM; Bhalla KN
Blood; 2019 Jul; 134(1):59-73. PubMed ID: 31023702
[TBL] [Abstract][Full Text] [Related]
2. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract][Full Text] [Related]
3. Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications.
Gonzales F; Barthélémy A; Peyrouze P; Fenwarth L; Preudhomme C; Duployez N; Cheok MH
Expert Opin Ther Targets; 2021 Apr; 25(4):299-309. PubMed ID: 33906574
[No Abstract] [Full Text] [Related]
4. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
[TBL] [Abstract][Full Text] [Related]
5. [Familial leukemia due to germline RUNX1 mutations: lessons learned from two decades of research and unsolved problems].
Osato M; Nambu A
Rinsho Ketsueki; 2020; 61(6):687-696. PubMed ID: 32624544
[TBL] [Abstract][Full Text] [Related]
6. [A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree].
Guan J; Wang LL; Wang CY; Zhu XM; Shuai HZ; Yi X; Zou L; Yu D; Cheng H
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):393-400. PubMed ID: 37032134
[No Abstract] [Full Text] [Related]
7. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
Simon L; Spinella JF; Yao CY; Lavallée VP; Boivin I; Boucher G; Audemard E; Bordeleau ME; Lemieux S; Hébert J; Sauvageau G
Blood; 2020 May; 135(21):1882-1886. PubMed ID: 32315381
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
Bluteau D; Gilles L; Hilpert M; Antony-Debré I; James C; Debili N; Camara-Clayette V; Wagner-Ballon O; Cordette-Lagarde V; Robert T; Ripoche H; Gonin P; Swierczek S; Prchal J; Vainchenker W; Favier R; Raslova H
Blood; 2011 Dec; 118(24):6310-20. PubMed ID: 21725049
[TBL] [Abstract][Full Text] [Related]
9. Unrelated hematopoietic stem cell transplantation for familial platelet disorder/acute myeloid leukemia with germline RUNX1 mutations.
Toratani K; Watanabe M; Kanda J; Oka T; Hyuga M; Arai Y; Iwasaki M; Sakurada M; Nannya Y; Ogawa S; Yamada T; Takaori-Kondo A
Int J Hematol; 2023 Sep; 118(3):400-405. PubMed ID: 36897502
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
[TBL] [Abstract][Full Text] [Related]
11. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.
Brown AL; Arts P; Carmichael CL; Babic M; Dobbins J; Chong CE; Schreiber AW; Feng J; Phillips K; Wang PPS; Ha T; Homan CC; King-Smith SL; Rawlings L; Vakulin C; Dubowsky A; Burdett J; Moore S; McKavanagh G; Henry D; Wells A; Mercorella B; Nicola M; Suttle J; Wilkins E; Li XC; Michaud J; Brautigan P; Cannon P; Altree M; Jaensch L; Fine M; Butcher C; D'Andrea RJ; Lewis ID; Hiwase DK; Papaemmanuil E; Horwitz MS; Natsoulis G; Rienhoff HY; Patton N; Mapp S; Susman R; Morgan S; Cooney J; Currie M; Popat U; Bochtler T; Izraeli S; Bradstock K; Godley LA; Krämer A; Fröhling S; Wei AH; Forsyth C; Mar Fan H; Poplawski NK; Hahn CN; Scott HS
Blood Adv; 2020 Mar; 4(6):1131-1144. PubMed ID: 32208489
[TBL] [Abstract][Full Text] [Related]
12. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
[TBL] [Abstract][Full Text] [Related]
13. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
14. Searching for germline mutations in the
Bąk A; Skonieczka K; Jaśkowiec A; Junkiert-Czarnecka A; Heise M; Pilarska-Deltow M; Potoczek S; Czyżewska M; Haus O
Leuk Lymphoma; 2021 Jul; 62(7):1749-1755. PubMed ID: 33563056
[TBL] [Abstract][Full Text] [Related]
15. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.
Preudhomme C; Renneville A; Bourdon V; Philippe N; Roche-Lestienne C; Boissel N; Dhedin N; André JM; Cornillet-Lefebvre P; Baruchel A; Mozziconacci MJ; Sobol H
Blood; 2009 May; 113(22):5583-7. PubMed ID: 19357396
[TBL] [Abstract][Full Text] [Related]
16. Myeloid neoplasms with germ line RUNX1 mutation.
Hayashi Y; Harada Y; Huang G; Harada H
Int J Hematol; 2017 Aug; 106(2):183-188. PubMed ID: 28534116
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21).
Lu L; Wen Y; Yao Y; Chen F; Wang G; Wu F; Wu J; Narayanan P; Redell M; Mo Q; Song Y
Theranostics; 2018; 8(8):2189-2201. PubMed ID: 29721072
[TBL] [Abstract][Full Text] [Related]
18. [Familial platelet disorder with predisposition to myeloid leukemia (FPD/AML): a case report and literature review].
Zhang RR; Chen XJ; Ren YY; Yang WY; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):308-312. PubMed ID: 33979975
[No Abstract] [Full Text] [Related]
19. Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.
Matsumura T; Nakamura-Ishizu A; Muddineni SSNA; Tan DQ; Wang CQ; Tokunaga K; Tirado-Magallanes R; Sian S; Benoukraf T; Okuda T; Asou N; Matsuoka M; Osato M; Suda T
Blood; 2020 Oct; 136(17):1919-1932. PubMed ID: 32573733
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets.
Glembotsky AC; Bluteau D; Espasandin YR; Goette NP; Marta RF; Marin Oyarzun CP; Korin L; Lev PR; Laguens RP; Molinas FC; Raslova H; Heller PG
J Thromb Haemost; 2014 May; 12(5):761-72. PubMed ID: 24606315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
